Three things changed the conversation about hormones in the last year: the FDA removed the decades-old boxed warning, demand for hormone therapy went vertical, and "peptides" became a wellness buzzword. Here is what I tell patients when they sit down across from me.
Is hormone therapy safe now that the FDA removed the black box warning?
On November 10, 2025, the FDA began removing the broad boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone-therapy labels. That warning had frightened two generations of women — and their doctors — away from treatment that works.
What the change means: the label now reflects the evidence more honestly, especially for women who start therapy near the onset of menopause and for low-dose vaginal estrogen. What it does not mean: hormones are risk-free or right for everyone. Systemic estrogen used without progesterone in a woman who still has a uterus still carries an endometrial-cancer warning. Personal and family history, clotting risk, breast history, and your goals still decide the plan.
The warning came off the box. That does not remove the need for a physician who actually reads your labs and your history.
Why is everyone suddenly asking about hormone therapy?
Search interest in hormone replacement therapy roughly doubled in a single week this summer, and estradiol patch prescriptions are up triple digits over two years. Demand outran supply, which is why so many women are calling three pharmacies to fill one prescription. If that is you, read what is really behind the estradiol patch shortage — and know that compounded creams, troches, capsules, injections, and pellets do not depend on the same finished-patch inventory.
What about peptides? Are they legit?
Peptides are short chains of amino acids that act as signals — telling tissue to repair, telling the pituitary to release growth hormone, telling appetite pathways to quiet down. Some are genuinely useful in the right patient; many products sold online are unregulated, mislabeled, or "research use only." My rule is simple: prescription-grade sourcing, a clear reason for using it, a defined endpoint, and labs to confirm we are helping rather than guessing. See peptide therapy for the protocols we actually use.
GLP-1 medications keep evolving — should I wait for the next one?
Dual and triple agonists are moving through development and the headlines. Waiting for a perfect future drug is rarely the right answer, because the part that determines your result has not changed: protein intake, resistance training, thyroid and hormone status, insulin resistance, and a dose that is titrated slowly enough to keep muscle. Rapid loss without hormone support is how women end up smaller, softer, and more tired. See GLP-1 and metabolic care, plus muscle loss on GLP-1 and plateaus.
My labs are "normal" but I feel terrible. Now what?
This is still the most common sentence I hear. Reference ranges describe a population, not your optimal. Symptoms like fatigue after 40, brain fog, early-morning waking, joint pain, histamine reactions, and POTS-type symptoms often show up long before a lab flags red. That is what advanced testing — DUTCH hormone metabolites, GI mapping, nutrient and toxicity panels — is for.
The bottom line
- The FDA change makes hormone therapy easier to discuss — it does not replace individualized evaluation.
- Shortages are real and workable; delivery method can be changed.
- Peptides and GLP-1s belong in a supervised plan with labs, not a shopping cart.
- "Normal" labs and a miserable life are not a diagnosis. They are a starting point.
If you have been putting off the conversation, a one-hour new-patient consultation is where we sort signal from noise. Call or text 479-715-3928.
Wondering if this is what's going on with you?
Dr. Tammy can help you connect the dots between your hormones and your symptoms — and build a plan that treats the cause, not just the pain.